Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Monika SztankayJohannes Maria GiesingerAugust ZaberniggElisabeth KremplerGeorg PallWolfgang HilbeOtto BurghuberMaximilian HochmairGerhard RumpoldStephan DoeringBernhard HolznerPublished in: BMC cancer (2017)
Our results indicate that HRQOL and symptom burden improve between first-line treatment to MT in some respects, although some late toxicity persists. Discrepancies between patients' and physicians' perception of reasons for rejecting MT were evident. Thus, the integration of patient-reported outcomes, such as HRQOL, is required to enable shared decision-making and personalised healthcare based on mutual understanding of treatment objectives.
Keyphrases
- patient reported outcomes
- advanced non small cell lung cancer
- healthcare
- end stage renal disease
- decision making
- epidermal growth factor receptor
- ejection fraction
- newly diagnosed
- small cell lung cancer
- primary care
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- patient reported
- social media
- combination therapy
- health information